Journal of the American Academy of Dermatology
Volume 63, Issue 3 , Pages 389-399 , September 2010

Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience

Preliminary results of this study were presented at the Ninth Annual Congress of the French Society of Nephrology and Dialysis, Lyon, France, September 10-13, 2007.

  • Anne A. Lemy, MD

      Affiliations

    • Department of Nephrology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
    • ,
  • Véronique del Marmol, MD, PhD

      Affiliations

    • Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
    • ,
  • Athanassios Kolivras, MD

      Affiliations

    • Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
    • ,
  • Whitney A. High, MD, MEng

      Affiliations

    • Dermatology Department, University of Colorado, Aurora, Colorado
    • ,
  • Celso Matos, MD

      Affiliations

    • Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
    • ,
  • Marianne Laporte, MD

      Affiliations

    • Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
    • ,
  • Joëlle L. Nortier, MD, PhD

      Affiliations

    • Department of Nephrology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
    • Corresponding Author InformationCorrespondence to: Joëlle Nortier, MD, PhD, Erasme Hospital, Universite Libre de Bruxelles, Route de Lennik, 808 1070 Brussels, Belgium.

,Accepted 24 October 2009.

References 

  1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001
  2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383–393
  3. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785–790
  4. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003;139:928–930
  5. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  6. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362
  7. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491–502
  8. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–26
  9. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27–30
  10. Khurana A, Greene JF, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol. 2008;59:218–224
  11. Baron PW, Cantos K, Hillebrand DJ, Hu KQ, Ojogho ON, Nehlsen-Cannarella S, et al. Nephrogenic fibrosis dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25:204–209
  12. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial. 2008;21:123–128
  13. Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2008;23:3280–3282
  14. Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis. 2009;53:133–137
  15. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543–2548
  16. Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol. 2008;69:161–168
  17. Maloo M, Abt P, Kashvap R, Younan D, Zand M, Orloff M, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant. 2006;6:2212–2217
  18. Evenepoel P, Zeegers M, Segaert S, Claes K, Kuypers D, Maes B, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004;19:469–473
  19. Hauser C, Kaya G, Chizzolini C. Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology. 2004;209:50–52
  20. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264–267
  21. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–157
  22. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433–3441
  23. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141–144
  24. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592
  25. Obermoser G, Emberger M, Wieser M, Zelger B. Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus. 2004;13:609–612
  26. Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol. 2007;57:105–111
  27. Bonnetblanc J-M, Michel J-P, Catanzano G, Gualde N, Loubet A, Leboutet JM, et al. Fibrose cutanée chez des hyperthyroïdiens traités par l'association sotalol-iode radioactif. Ann Dermatol Venereol. 1979;106:583–588
  28. Ahmad S. Association of metoprolol and retroperitoneal fibrosis. Am Heart J. 1996;131:202–203
  29. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 2008;73:1413–1418
  30. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Int Med. 2006;145:234–235
  31. Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology. 2009;253:390–398
  32. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163:993–1000
  33. Deng AC, Bilu Martin D, Sina B, Gaspari A. Localized nephrogenic fibrosing dermopathy: aberrant dermal repairing?. J Am Acad Dermatol. 2008;58:336–339
  34. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18:2636–2643
  35. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238–249
  36. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903–906
  37. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54:31–34
  38. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy. Arch Pathol Lab Med. 2006;130:209–212
  39. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65–75
  40. Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44:226–233

 Dr High's work in this general area is supported by a Career Development Award in Medical Dermatology from the Dermatology Foundation.

 Conflicts of interest: None declared.

 Reprints not available from the authors.

PII: S0190-9622(09)01370-X

doi: 10.1016/j.jaad.2009.10.038

Journal of the American Academy of Dermatology
Volume 63, Issue 3 , Pages 389-399 , September 2010

Article Tools

* Image Usage & Resolution